Comparisons › MRNA / PFE
Moderna vs Pfizer: comparing MRNA and PFE stock
12-month growth, from 100━ MRNA +924.9% ━ PFE +27.7%
| Metric | MRNA | PFE |
|---|---|---|
| Price, $ | 241.46 | 29.88 |
| Year to date | +718.8% ● | +24.0% |
| 12 months | +924.9% ● | +27.7% |
| From 52-week high | −7.5% | −5.0% ● |
| vs 200-day average | +167.0% ● | +11.8% |
| P/E | — | 9.8 |
| Dividend yield | 0.00% | 5.64% ● |
| Revenue growth, YoY | −27.6% | +1.3% ● |
| Operating income growth | — | +8.5% |
| Operating margin | −109.3% | 29.0% ● |
| Gross margin | −66.0% | 74.9% ● |
| Market cap | $96.4B | $170.3B |
| Next earnings | Nov 6, 2026 | Feb 2, 2027 |
● — whose figure is higher, not which is better. Data as of Nov 5, 2026.
Ratings and a detailed chart for each are in the terminal.
Open the terminalFAQ
Which is better to buy: Moderna or Pfizer?
We do not advise what to buy. By the numbers: Moderna rose more over the year (+924.9%); Pfizer is closer to its 52-week high; Pfizer has the higher operating margin; Pfizer is growing revenue faster. How to weigh such signs is covered in «How to analyse a stock».
Can I buy both?
Yes. Many hold several companies in one industry to avoid depending on one. A broad index fund often already holds the largest US companies.
When do they report?
Moderna — Nov 6, 2026; Pfizer — Feb 2, 2027.